Functional precision medicine

DEVICE2 trials

Sponsors

Florida International University, First Ascent Biomedical Inc.

Conditions

Metastatic Colon AdenocarcinomaMetastatic Colon CancerMetastatic Rectal AdenocarcinomaMetastatic Rectal CarcinomaMetastatic Rectum CancerRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Brain Tumor

Phase 1

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

RecruitingNCT05857969

Florida International UniversityRecurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brainstem Glioma +15

Start: 2023-02-22End: 2028-12-31Target: 65Updated: 2026-08-26

Unknown Phase

xDRIVE in Metastatic Colorectal Cancer

WithdrawnNCT06929338

First Ascent Biomedical Inc.Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma +2

Start: 2025-09-15End: 2027-06-30Updated: 2026-09-02

Related Papers

Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.

Journal of Clinical Oncology2024-06-012 citations

Biomarker development from functional precision medicine datasets via explainable machine learning.

Journal of Clinical Oncology2024-06-01

Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers

Nature Medicine2024-04-0145 citations